In summary, both MAPK14 and ATF2 were identified as novel target genes of miR-622 in HCC, outlining this microRNA as a master regulator of the drug resistance associated MAPK14-ATF2 and RAS-RAF-ERK pathways. This evidence concerns the gene MAPK14 and hepatocellular carcinoma.